modipafant has been researched along with reparixin in 1 studies
| Studies (modipafant) | Trials (modipafant) | Recent Studies (post-2010) (modipafant) | Studies (reparixin) | Trials (reparixin) | Recent Studies (post-2010) (reparixin) |
|---|---|---|---|---|---|
| 29 | 3 | 3 | 70 | 4 | 48 |
| Protein | Taxonomy | modipafant (IC50) | reparixin (IC50) |
|---|---|---|---|
| C-X-C chemokine receptor type 1 | Homo sapiens (human) | 0.0031 | |
| C-X-C chemokine receptor type 2 | Homo sapiens (human) | 0.0354 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arantes, EC; Coelho, AM; Coelho, FM; Pessini, AC; Pinho, VS; Souza, DG; Teixeira, AL; Teixeira, MM | 1 |
1 other study(ies) available for modipafant and reparixin
| Article | Year |
|---|---|
Platelet activating factor receptors drive CXC chemokine production, neutrophil influx and edema formation in the lungs of mice injected with Tityus serrulatus venom.
Topics: Animals; Chemokines, CXC; Dihydropyridines; Dose-Response Relationship, Drug; Edema; Granulocyte Colony-Stimulating Factor; Imidazoles; Interleukin-3; Lung Diseases; Male; Mice; Neutrophils; Platelet Membrane Glycoproteins; Receptors, G-Protein-Coupled; Recombinant Fusion Proteins; Recombinant Proteins; Scorpion Venoms; Scorpions; Sulfonamides; Time Factors | 2007 |